| Pre-conference and additional meetings | ||||
| Tuesday 10 June & Wednesday 11 June |
International Physiotherapy Group/CF -
11/2
day Physiotherapy Short Course. Course Title: Airway Clearance Techniques |
|||
| Wednesday 11 June | International Physiotherapy Group/CF AGM & Case Presentations European CF Nutrition Group Meeting International Nurses Group/CF Meeting Psychosocial Special Interest Group Meeting Joint International Nurses Group/CF & Psychosocial SIG Meeting Pre-conference Programme (in more detail) |
|||
| EuroCareCF programme | ||||
| CF Worldwide programme 10 & 11 June | ||||
| ECFS Meetings | ||||
| Tuesday 10 June 09:00-17:00 |
ECFS Board Meeting | |||
| Wednesday 11 June 12:00-14:00 |
ECFS Neonatal Screening Working Group Meeting | |||
| Wednesday 11 June 14:00-17:00 |
ECFS Diagnostic Working Group (see link to EuroCareCF programme above) | |||
| Wednesday 11 June 17:00-18:00 |
ECFS Annual General Meeting | |||
| ERS/ECFS Advanced Course - Part II | ||||
| Wednesday 11 June - 10:00-17:00 | ||||
| Exhibition | ||||
| Wednesday 11 June Evening |
Exhibition Opens The exhibition area is located adjacent to the meeting facilities, and will also serve as the area for coffee breaks. |
|||
| Conference programme | ||||
Full
Conference Programme -
here
- updated 31 May 2008A copy of the programme will be part of the delegates' registration materials |
||||
| Wednesday 11 June 18:30 |
Opening Ceremony ECFS Award Young Investigators Awards Welcome Reception |
|||
| Overview 12-14 June | ||||
| Thursday 12 June | ||||
| 07:30-08:15 | Round Tables (Link to objectives) | |||
| 08:30-10:00 | Plenary I - Translating Laboratory
Discoveries to Patient Benefit: What do we still need to know to stop CF lung damage |
|||
| 10:00-10:30 | Coffee Break | |||
| 10:30-12:00 | Symposium 1 - Pro/Con Debate | |||
| Symposium 2 - Bacterial physiology in the niches of the CF lung | ||||
| Symposium 3 - Cystic Fibrosis related diabetes | ||||
| Symposium 4 - Glands and mucus versus surface epithelium | ||||
| Symposium 5 - Freedom from pain and suffering - effective interventions | ||||
| Poster Session 1: Genetics / Registry: CF around the World | ||||
| 12:00-14:30 | Lunch | |||
| 12:30-14:00 | Satellite Symposium Endpoints for clinical trials in cystic fibrosis: Patients know best? |
|||
 |
Symposium Agenda |
|||
| 12:00-14:00 | ECFS/EuroCareCF CF Registry Steering Committee | |||
| 13:30-14:30 | Guided Poster Tours:
GI/Nutrition/Metabolic Complications; Microbiology; Psychosocial issues/Nursing |
|||
| 13:30-14:30 | Poster presenters in the following categories available at their poster for discussion: Pulmonology/Immunology/Inflammation/New Therapies | |||
| 13:30-14:30 | CF Aging Group Meeting | |||
| 14:30-16:00 | Workshop 1 - Adherence: An old problem, new ideas | |||
| Workshop 2 - Impact of Mutations on CFTR Structure and on Interacting Proteins | ||||
| Workshop 3 - Endocrine Complications in Cystic Fibrosis | ||||
| Workshop 4 - Quantification of severity of lung disease | ||||
| Workshop 5 - New therapies treating the basic defect | ||||
| Poster Session 2: Microbiology: Basics to bedside | ||||
| 16:00-16:30 | Coffee Break | |||
| 16:30-18:00 | Workshop 6 - Personalized CF Genetics | |||
| Workshop 7 - Virulence factors and pathogenesis | ||||
| Workshop 8 - Exercise in CF | ||||
| Workshop 9 - Complications in CF: What can we learn - and not learn - from the Registries | ||||
| Workshop 10 - Selected clinical issues in nursing and psychosocial practice | ||||
| Poster Session 3: Pulmonology / New Therapies | ||||
| 18:15-19:15 | EuroCareCF / ECFS CF Registry Meeting | |||
| 18:30-21:00 | EuroCareCF WP1 - CF treatment
focused on adult patient issues For further information, please click
here |
|||
| 18:30-21:30 | EuroCareCF WP5 - Pro-Con debate on gene
therapy for CF (For more information see link to EuroCareCF programme above) |
|||
| Friday 13 June | ||||
| 07:30-08:15 | Round Tables (Link to objectives) | |||
| 07:30-08:30 | Journal of Cystic Fibrosis Editorial Board Meeting | |||
| 08:30-10:00 | Symposium 6 - New Therapies: Tailored therapies for CF Mutations | |||
| Symposium 7 - Hepatobiliary Disease in CF | ||||
| Symposium 8 - Grand rounds in pulmonary disease | ||||
| Symposium 9 - Physiology of airway clearance | ||||
| Symposium 10 - Quality indicators and patient satisfaction | ||||
| 10:00-10:30 | Coffee Break | |||
| 10:30-12:00 | Symposium 11 - Data from European Registries | |||
| Symposium 12 - CFTR (Dys)functions | ||||
| Symposium 13 - Inhaled Medications and Devices | ||||
Symposium 14 - Anti-infective therapies
|
||||
| Symposium 15 - Nutritional Support of the CF Patient | ||||
| 12:00-14:30 | Lunch | |||
| 12:30-14:00 | Satellite Symposium: Striving for excellence: Optimising CF patient care today |
|||
 |
Invitation
to the Symposium |
|||
| 13:30-14:30 | Guided Poster Tours:
Screening/Diagnosis/Genetics; CFTR/Cell Biology/Physiology; Physiotherapy |
|||
| 13:30-14:30 | Poster Presenters in the following categories available at their posters for discussion: Registry, Other Issues | |||
| 12:10-14:30 | EuroCareCF Steering Committee/Advisory Committee Meeting | |||
| 13:30-14:30 | International Psychosocial Study on Depression - Update Meeting | |||
| 14:30-16:00 | Workshop 11 - Novel Treatments for pulmonary disease in CF | |||
| Workshop 12 - GI Case Presentations | ||||
| Workshop 13 - CFTR: From molecular to tissue function | ||||
| Workshop 14 - QoL in registries | ||||
| Workshop 15 - New trends in Physiotherapy | ||||
| 16:00-16:30 | Coffee Break | |||
| 16:30-18:00 | Workshop 16 - Late Breaking Science | |||
| Workshop 17 - Focus on Inflammation | ||||
| Workshop 18 - Genetics and screening | ||||
| Workshop 19 - Infection control | ||||
| Workshop 20 - Psychosocial and Nursing Complex Case Presentations and Responses | ||||
| Poster Session 4: GI / Nutrition | ||||
| 20:30 | Conference Dinner and Party | |||
| Saturday 14 June | ||||
| 09:00-10:30 | Symposium 16 - Transplantation | |||
| Symposium 17 - Quality Improvement in CF | ||||
| Symposium 18 - Mechanisms of early pulmonary disease | ||||
| Symposium 19 - Consensus in Screening and Diagnosis | ||||
| Symposium 20 - Communication: Understanding and Misunderstanding | ||||
| 10:30-11:00 | Coffee Break | |||
| 11:00-12:30 | Closing Plenary | |||
| 12:30-13:00 | Closing Ceremony | |||
| 14:00-18:30 | Scientific Committee Meeting, Brest 2009 | |||
| Round Tables | 12 June | 13 June | |
| Physiotherapy | Managing Urinary Incontinence
Leader: M. Dodd (UK) "The objective of the Round Table is to review the current literature in CF and discuss the active and prophylactis management of urinary incontinence" |
Aging in CF - from the
physiotherapy perspective Leader: B. Button (AU) "The objective is to discuss the challenges for physiotherapists that growing older with CF presents. These challenges include airway clearance therapy and exercise in older patients where problems in other organs result in modification of usual treatment e.g. cardiac, renal and liver disease, pregnancy, diabetes, eating disorders etc." |
|
|
Nurse/ Psychosocial |
Fertility and
pregnancy Leader: G. Thorpe-Beeston (UK) "The objectives are to discuss and share current experience concerning fertility issues and the management of pregnancy in CF. Special consideration will be given to attempting to define those women most at risk in pregnancy and whether pregnancy compromises long term outcome" |
The role of
the Nurse in the CF Team Leader: D. Sheehan (UK) "The aim of this roundtable is to discuss the many tasks required of the nurse in the CF team and variability in these internationally, as well as examining the appropriate role and function of the nurse within the team. Ideally, a useful outcome would be to devise a list of primary and secondary tasks and identify any training needs" |
|
|
Infection control Leader: F. Festini (IT) "The goal of this RT is to discuss and compare different strategies to reduce the risk of respiratory cross infection in CF Centres, the available evidence of effectiveness, the obstacles to their implementation" |
Using patient drawings in
clinical practice Leader: D. Kadosh (IL)
"This round table will give an overview about the
use of drawings for connecting with children,
assessing their emotional status, helping them to
understand their body and treatments
better, and allowing self expression in a
therapeutic setting"
|
||
|
Gender
Differences Leader: |
|||
|
Registry/ Epidemiology |
Survival analysis from
registries. Methods and Pitfall. Recording bias Leader: J. Dodge (UK) "The objective is to discuss Methods of Survival Analysis from Registries, and to consider Pitfalls and minimising Recording Bias" |
Implementation of QoL in
registries Leader: J. Abbott (UK) "The objective of this Round Table is to evaluate the feasibility, advantages and limitations of implementing and utilising health-related quality of life data in registries" |
|
|
DM and
registries - relevant variables Leader: K. Gyi (UK)
CFRD and registries relevant variables |
Experience
with PortCF Leader: A. Linblad (SE) "What information can we get from PortCF? How difficult is it to use?" |
||
| New Therapies | Home IV therapy: who, how, legal
issues Leader: M. Proesmans (BE) "The aim of this round table is: - To review the literature on home IV therapy in CF with regard to outcome, QOL, economical aspects - To discuss with the participants their own practice and view on home IV in the light of the existing literature" |
CF and hygiene in the home, too
little, too much Leader: M. Denton (UK) "A practical discussion regarding the microbial threats contained with the home environment and the advice we should give. Of interest to CF clinicians, microbiologists, and CF nurse specialists alike" |
|
|
CF at school Leader: I. Sermet (FR) "The objective of the round table is to discuss specific amenities in Europe for CF patients at school: individual education plans, national laws for individuals with disabilities or other specific amenities" |
Anti-fungal
treatment Leader: C. Knoop (BE)
"The objectives of this
round-table "anti-fungal treatment" are
1) review current established
and potential indications and treatment schedules for
anti-fungal treatment in non-transplanted CF patients as
well as
2) review currently available
anti-fungal drugs, their mechanisms of action, special
pharmacokinetics issues in CF patients, interactions with
other common drugs used for the treatment of CF
and common/uncommon side effects"
|
||
| Pulmonology | When to start treatment in a
screened baby Leader: A. Malfroot (BE) "It is clearly shown that early intervention after neonatal CF screening leads to nutritional benefits and to an opportunity for better pulmonary outcome. However benefit of early pulmonary treatment on outcome is more difficult to prove" |
Paediatric lung transplant Leader: C. Benden (CH) "Objectives: - to appreciate controversial issues in patient selection for paediatric lung transplantation - to update on latest developments in the management of paediatric lung transplant recipients" |
|
|
Exercise
testing in children Leader: H. Hebestreit (DE) "Participants of the Round Table will discuss the indications for exercise testing in children with cystic fibrosis, the selection of the appropriate exercise protocol, the interpretation of measurements taken during the test and the recommendations given to the patients" |
Pulmonary function testing in infants and young children Leader: S. Ranganathan (AU) "We will explore the role of lung function testing in an era of newborn screening, its relationship with other modalities for the early detection of pulmonary disease and its potential as an outcome measure in future intervention studies in pre-school children with CF" |
||
| Is it possible to decrease the
burden of treatment? Leader: I. Balfour-Lynn (UK) "The session will explore the principles of reducing the burden of treatments rather than the usual clinical practice, which is to keep adding more treatments to the overloaded families. It should help prioritise the most important therapies which should aid the poorly adherent patients" |
Management of sinus disease Leader: M. Hodson (UK)
"Sinus disease is almost
universal among adults with cystic fibrosis.
Correct management can improve pulmonary disease" |
||
|
Difficult
diagnosis Leader: K. Southern (UK) "Although straight forward in the majority, the diagnosis of CF is difficult in a small but significant number of children (and adults). We will discuss the investigation and clinical and social management of these patients, with particular focus on the impact on such a situation on the family and child" |
|||
|
Mechanisms of inflammation Leader: G. Döring (DE) "The objectives of this RT are to discuss (1) the major current hypotheses concerning the mechanisms of inflammation in CF patients as a consequence of mutations in CFTR, particularly the question whether inflammation precedes infection or whether infection precedes inflammation, and (2) how inflammation can be therapeutically addressed based on the various hypotheses" |
|||
| Genetics/ Screening |
Interpretation
of the laboratory genetic analysis report Leader: C. Castellani (IT) "At this Round Table, it will be discussed what information the molecular genetics laboratories need from the clinicians, what should be included in a standard molecular analysis laboratory report, and how this should be interpreted" |
Pitfalls with
CF neonatal screening programme Leader: I. Doull (UK) "The aims of this Round Table are: To discuss pitfalls between the birth of the infant to the eventual diagnosis, to include false negatives, broaching the possibility of CF, making the diagnosis and communicating with the family" |
|
| Mutation specific therapies Leader: B. Kerem (IL) "The objectives of this Round Table "Mutation specific therapies" is to discuss progress in the development of new therapeutic approaches for the different classes of CFTR mutations" |
|||
| Gastroenterology/ Nutrition |
Managing constipation and DIOS Leader: C. Taylor (UK) "The round table will focus on the aetiology and management of constipation and distal ileal obstruction in cystic fibrosis. Delegates will be encouraged to discuss management strategies adopted in their own centre and compare outcomes with other centres" |
Abdominal pain
in CF Leader: J. Walkowiak (PL) |
|
| Optimising growth and
nutritional status of CF infants Leader: A. Munck (FR)
"The increased implementation
of CF newborn screening programmes enables very early
diagnosis. We will discuss the modalities of optimising
growth as it is a major goal for CF care centres to
achieve."
|
Nutritional Assessment in CF Leader: A. Morton (UK) "To determine the most appropriate methods of assessment of nutritional status in clinical practice.
To review the validity of
different methods of assessing dietary intake. |
||
| Microbiology/ Antibiotics |
Antibiotic
resistance - does it matter? Leader: J. Foweraker (UK) "To explore the role of the microbiology laboratory in testing susceptibility to single or combined antibiotics and the relevance of these results to the treatment of patients, either to clear early infection or to treat acute exacerbations of chronic lung infection" |
Non-tuberculous mycobacteria Leader: B. Fauroux (FR) "Non-tuberculous mycobacteria are increasingly recovered from the respiratory secretions in patients with cystic fibrosis. Important uncertainties exist about the significance and the management of these micro-organisms in cystic fibrosis, especially within the context of lung transplantation. During this round table, the management of non-tuberculous mycobacteria, with a special interest for mycobacterium abscessus, will be discussed" |
|
| Use of
microarrays in microbiology Leader: P. Drevinek (UK) "We will be discussing how the microarray technology can be exploited to study CF pathogens. Researchers with personal experience in this field are most welcome" |
Cross-infection and segregation
in and out of hospital Leader: J. Govan (UK) "The aims of this Round Table are to allow discussion of current data, guidelines and attitudes on cross-infection control and segregation in clinics, social settings and schools" |
||
|
Quorum sensing - prospects for
new therapy Leader: M. Givskov (DK) |
Pseudomonas
antibody - diagnostic use Leader: T. Pressler (DK) |
||
| Basic Science |
Mechanisms of
Lung Disease in CF Leader: M. Mall (DE) "This roundtable will discuss the current concepts of the in vivo pathogenesis and therapeutic interventions that target initiating lesions of CF lung disease" |
Host-Pathogen
Interactions Leader: P. Sokol (CA) "The objectives of this roundtable are to discuss pathogen virulence factors that influence lung host defense mechanisms and host modulation of pathogen virulence factors with a primary focus on Pseudomonas aeruginosa and Burkholderia cepacia complex" |
|
|
CFTR structure: Why is it really
important? Leader: P. Lehn (FR) "Following a brief introduction to the present state-of-the-art, the RT should allow the participants to discuss how further progress may permit a better insight into the functioning of the CFTR protein and into the molecular consequences of some specific mutations" |
CFTR interacting proteins: the
devil is in the detail? Leader: M. Amaral (PT) "The number of CFTR-interacting proteins (CIPs) has been continuously increasing and include various functional classes, namely (i) chaperones that direct the biogenesis of CFTR, (ii) proteins that control the traffic and cellular location of CFTR and (iii) kinases and phosphatases that regulate CFTR channel activity. In this roundtable, we will discuss recently identified CIPs and how novel roles are emerging for these key partners of CFTR in dynamic multiprotein complexes" |
||
| Back to top
|
|||